1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sexual Medicine Society of North America (SMSNA)/American Urological Association (AUA) telemedicine and men’s health white paper
    Review

    Khera, M.; Bernie, H. L.; Broderick, G.; Carrier, S.; Faraday, M.; Kohler, T.; Jenkins, L.; Watter, D.; Mulhall, J.; Raheem, O.; more...
    Journal of Sexual Medicine (2024)

    Fulltext@MSK | Save
  • Genomic classification and individualized prognosis in multiple myeloma
    Journal Article

    Maura, F.; Rajanna, A. R.; Ziccheddu, B.; Poos, A. M.; Derkach, A.; Maclachlan, K.; Durante, M.; Diamond, B.; Papadimitriou, M.; Davies, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J.; Goh, J. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: A phase Ib/II study
    Journal Article

    Flowers, C. R.; Matasar, M. J.; Herrera, A. F.; Hertzberg, M.; Assouline, S.; Demeter, J.; McMillan, A.; Mehta, A.; Opat, S.; Trněný, M.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended follow-up from the phase III randomised CheckMate 9ER trial
    Journal Article

    Powles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer
    Journal Article

    Tan, T. J.; Sammons, S.; Im, Y. H.; She, L.; Mundy, K.; Bigelow, R.; Traina, T. A.; Anders, C.; Yeong, J.; Renzulli, E.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: Phase II feasibility study
    Journal Article

    Krul, M. F.; Kok, N. F. M.; Osmani, H.; Buisman, F. E.; Koerkamp, B. G.; Grunhagen, D. J.; Verhoef, C.; Mostert, B.; Snaebjornsson, P.; Westerink, B.; more...
    British Journal of Surgery (2024)

    Fulltext@MSK | Save
  • A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Journal Article

    Lee, V.; Parkinson, R.; Zahurak, M.; Cope, L.; Cercek, A.; Verheul, H.; Gootjes, E.; Lenz, H. J.; Iqbal, S.; Jones, P.; more...
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Safety analyses of the phase 3 VISION trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Journal Article

    Chi, K. N.; Armstrong, A. J.; Krause, B. J.; Herrmann, K.; Rahbar, K.; de Bono, J. S.; Adra, N.; Garje, R.; Michalski, J. M.; Kempel, M. M.; more...
    European Urology (2024)

    Fulltext@MSK | Save